greater human leukocyte antigen (HLA) disparity between donor and recipient and with immunocompromised states induced by pancytopenia and immunosuppressive agents. VOD of the liver is an early and the major complication of BMT (7, 8) . Typical clinical features of VOD include hyperbilirubinemia, painful hepatomegaly, and fluid retention (9, 10) . Histopathologically, VOD is characterized by deposition of factor VIII and fibrinogen in the subendothelial zones of affected venules and by necrosis of hepatocytes in zone 3 of the liver acinus (11) . Endothelial cell injury caused by conditioning regimens of radiation-chemotherapy contributes to VOD of the liver (10, 12) , TMA (13) (14) (15) , and GVHD (16, 17) . In patients with VOD, high circulating levels of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) and low circulating levels of fibrinogen have been reported during the post-transplant period (18) . Significantly low plasma levels of antithrombin (AT) and plasminogen were also reported before the diagnosis of VOD (18) . Decreased plasma levels of AT and protein C (PC) were reported in patients after BMT with moderate to severe VOD (19) , and plasma levels of AT or PC reflect the early occurrence of complications associated with poor prognosis (20) . Plasma thrombomodulin (TM) values on day 14 after BMT were significantly elevated in patients with TMA (21) . Plasma levels of F1+2 and thrombin-antithrombin complex (TAT) were high before BMT and plasmin-plasmin inhibitor complex (PPIC) was elevated after BMT (22) . In a previous study, treatment with AT concentrate improved post-BMT chemotherapy-induced organ failure (23) . It was reported that serum interleukin (IL)-6 progressively increased until 2 weeks after BMT and declined thereafter (24) . Following BMT, donor T-cells undergo apoptosis during GVHD. Active apoptosis is mediated via Fas/Fas-ligand. Patients with GVHD show a significant increase of both Fas and Fas-ligand (25) .
This study was designed to determine the long-term dynamic changes following BMT in patients with hematologic disorders and to evaluate the relationship between hemostatic abnormalities and prognosis. For this purpose, we measured various hemostatic parameters weekly for 12 weeks in patients treated with BMT.
SUBJECTS AND METHODS
The subjects comprised 39 patients treated with allogeneic BMT (Table 1) . We examined hemostatic changes in these patients before and after BMT. The underlying diseases of the patients were chronic myelocytic leukemia (CML: n=21), acute myeloblastic leukemia (AML: n=5), acute lymphoblastic leukemia (ALL: n=3), myelodysplastic syndrome (MDS: n=7), severe aplastic anemia (SAA: n=1), non-Hodgkins lymphoma (NHL: n=1), and multiple myeloma (MM: n=1). All patients were transplanted from HLA-matched donors or one-locus mismatched donors. The mean age of the patients was 37.4 ± 12.1 years (20 males and 19 females; range, 17-64 years). The conditioning regimens of BMT were as follows: BU/CY: busulphan (BU) 1 mg/kg (4 times/day × 4 days) (16 mg/kg; p.o.) + cyclophosphamide (CY) 60 mg/kg/day × 2 days (120 mg/kg; div), TBI/CY: total body irradiation (TBI) 2 gray × 6 times (12 gray fractionated) + CY 60 mg/kg/day × 2 days (120 mg/kg; div), TBI/AraC/CY: TBI 2 gray × 6 times (12 gray fractionated) + AraC 2 g/m 2 (2 times/day × 2 days) (8 g/m 2 ) + CY 60 mg/kg/day × 2 days (120 mg/kg; div), BU/CY/AraC, AraC/TBI, BU/CY/TBI. The study protocol was approved by the Human Ethics Review Committee of Mie University School of Medicine.
Twenty-six patients who survived for 6 months after BMT were categorized as the "survivor" group and 13 patients who died within 6 months after BMT were categorized as the "non-survivor" group. Furthermore, 13 survivors without acute GVHD or severe complications such as infections, TMA, or VOD were categorized as the "event-free" group. Seventeen patients with acute GVHD were categorized as the "GVHD group." Twenty-six patients with severe organ failure such as acute GVHD, VOD, TMA, or infection were categorized as the "complication group." We diagnosed acute GVHD, TMA, or VOD according to the guidelines of The Japan Society for Hematopoietic Cell Transplantation.
Blood samples were obtained from the patients before BMT and then every week after BMT. For the assays, whole blood was anticoagulated by the addition of 9 volumes of blood to 1 volume of 3.8% trisodium citrate solution. The activity of plasma AT and PC was measured by amidolytic assays using Berichrom AT III and Berichrom Protein C (Behringwerke, Marburg, Germany). The plasma level of thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), FDP-Ddimer, soluble fibrin (SF), thrombomodulin (TM), and tissue plasminogen activator-plasminogen activator inhibitor-1 complex (tPA-PAI-1 complex) was determined with TAT-test-Kokusai-F (Kokusai-shiyaku, Koube, Japan), PIC-test-Kokusai-F (Kokusai-shiyaku), D-dimer test-Kokusai-F (Kokusai-shiyaku), Enzymun test (Boehringer Mannheim, Mannheim, Germany), TM-test-Kokusai (Kokusai-shiyaku) and tPAIc-Kokusai (Kokusai-shiyaku), respectively. Plasma antigen levels of P-selectin (Granular Membrane of 140Kd; GMP-140), IL-6, Fas, and Fas-ligand were measured by enzyme-linked immunosorbent assay (ELISA) using GMP-140 (P-selectin) EIA Kit (TaKaRa, Otsu, Japan), human IL-6 ELISA Kit (TFB Inc, Tokyo, Japan), sFas(S) ELISA Kit (Medical & Biological Laboratories Co., Nagoya, Japan), and human blood Fas-Ligand EIA Kit (Mochida Co., Tokyo), respectively. Data were expressed as the mean ± standard deviation. Statistical differences between two groups were assessed using the Mann-Whitney U-test (two-sided). 
RESULTS
In this study, 26 of 39 patients survived and 13 of 39 patients died within 6 months after BMT. The causes of death included acute GVHD (n=6), VOD (n=2), and TMA (n=2). Among the 39 patients, 17 experienced acute GVHD, 6 patients had VOD and 3 had TMA (Table 1 ). There was no significant difference in plasma levels of AT, PC, TAT, PPIC, tPA-PAI-1 complex, GMP-140, IL-6, or Fas-ligand between the non-survivor and survivor groups at 1 to 4, 5 to 8, and 9 to 12 weeks. Plasma levels of D-dimer were significantly higher in the non-survivor than in the survivor group at 1 to 4 weeks (p< 0.01) and 5 to 8 weeks (p< 0.05). Plasma levels of SF were significantly higher in the non-survivor than in the survivor group at 1 to 4 weeks (p< 0.05). Plasma levels of TM were significantly higher in the nonsurvivor than in the survivor group at 1 to 4, 5 to 8, and 9 to 12 weeks (p< 0.05, respectively). Plasma levels of Fas were significantly higher in the non-survivor than in the survivor group at 1 to 4 weeks (p< 0.01). Data were selected from the first week of each period for survivors, but at the week in which the patient died in the nonsurvivor groups ( Table 2) .
There was no significant difference in plasma levels of AT, PC, PPIC, TM, Fas-ligand, or Fas between the event-free group and complication group. Plasma levels of TAT were significantly higher in the complication group than in the event-free group at 5 to 8 weeks. Plasma levels of D-dimer were significantly higher in the compli- cation group than the event-free group at 1 to 4, 5 to 8, and 9 to 12 weeks (p<0.05, respectively). Plasma levels of tPA-PAI-1 complex were significantly higher in the complication group than in the event-free group at 9 to 12 weeks. Plasma levels of GMP-140 were significantly higher in the event-free group than in the complication group at 5 to 8 and 9 to 12 weeks. Plasma levels of IL-6 were significantly lower in the complication group than in the event-free group at 5 to 8 weeks (p<0.05). Data for the event-free group were selected from the first week in each period. Data for the complication group were selected from the week of complications or the week nearest to when complications occurred (Table 3 ).
There was no significant difference in plasma levels of AT, PC, PPIC, SF, TM, IL-6, Fas-ligand, or Fas between patients in the event-free group and in the GVHD group. Plasma levels of TAT and D-dimer were significantly higher in the GVHD group than in the event-free group at 1 to 4, 5 to 8, and 9 to 12 weeks. Plasma levels of tPA-PAI-1 complex were significantly higher in the GVHD group than in the event-free group (p< 0.05). Plasma levels of GMP-140 were significantly lower in the GVHD group than in the event-free group at 1 to 4 and 5 to 8 weeks (p< 0.05) ( Table 4 ).
DISCUSSION
In this study, 33% of patients who were treated with BMT died within 6 months, suggesting that BMT remains a high-risk treatment. Transplant-related mortality was reported to be 29% to 47% in patients with leukemia (26) . However, BMT is a final and important therapy for hematologic disorders or malignant diseases. The primary causes of death in this study included acute GVHD (32%), VOD (11%), and TMA (11%). Among all 39 patients, acute GVHD occurred in 41%, VOD in 18%, and TMA in 8%. Acute GVHD was reported to develop in 29% to 50% of patients with leukemia treated with BMT (26) . These results indicate that acute GVHD is the most important complication or risk factor in BMT. Plasma levels of D-dimer, SF, and TM were significantly elevated in the non-survivor group at 1 to 4 weeks, suggesting that these parameters might be increased due to VOD. VOD usually develops within 3 weeks after BMT (27) . Plasma levels of TM were significantly elevated in the non-survivor group at 1 to 8 weeks ( Fig. 1) .
Increased plasma levels of TM are considered to reflect vascular endothelial cell injuries and poor outcome in patients with BMT (28) , such as those with disseminated intravascular coagulation (DIC) or thrombotic thrombocytopenic purpura (TTP) (29, 30) . Increased plasma levels of SF and D-dimer indicate the presence of a hypercoagulable state. That is, hypercoagulability and vascular endothelial cell damage are associated with VOD. Plasma levels of Fas were significantly elevated in the non-survivor group at 1 to 4 weeks. Although soluble Fas levels were significantly increased in patients with acute GVHD (31) (32) (33) , plasma levels of Fas were not significantly elevated in the GVHD group in this study. However, Fas may be associated with the devel- (ng/ml) opment of VOD. Plasma levels of D-dimer and TM were high in the non-survivor group at 5 to 8 weeks, suggesting that these parameters might be increased in acute GVHD. Acute GVHD is also considered to be associated with hypercoagulability and vascular endothelial cell damage. Plasma levels of TAT, D-dimer, and tPA-PAI-1 complex were significantly elevated, suggesting that hypercoagulability and organ failure may be associated with complications of BMT (Figs. 2, 3) . Plasma levels of tPA-PAI-1 complex were reported to be elevated in DIC patients with poor outcomes or organ failure (34) . Plasma levels of GMP-140 were significantly low in the complication group at 5 to 8 and 9 to 12 weeks, indicating that thrombocytopenia in BMT patients may be associated with poor outcome (35) . GMP-140 is found in the alpha-granules of platelets and in the Weibel-Palade bodies in endothelial cells. However, endothelial cell activation is associated with an increased GMP-140 concentration per platelet (36) . Platelets are the major source of circulating GMP-140 in healthy individuals.
In this study, plasma levels of AT, PC, and TM were not significantly different between the GVHD group and the event-free group. It was previously reported that plasma TM levels were higher in moderate or severe acute GVHD than in no or mild acute GVHD (37) . Plasma levels of TAT and D-dimer were significantly elevated in the GVHD group at 1 to 12 weeks, suggesting that a hypercoagulable and hyperfibrinolytic state exists in GVHD. Plasma levels of tPA-PAI-1 complex were also high in the GVHD group. GVHD patients were previously reported to have significantly high levels of tPA-PAI-1 complex on day 14 (38) .
In conclusion, we demonstrated in this study that abnormalities in most hemostatic parameters are associated with BMT, suggesting that these investigations following BMT might be useful for predicting complications of BMT.
